Clinical Trial Detail

NCT ID NCT02339324
Title Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Pittsburgh
Indications

melanoma

Therapies

Interferon alpha-2b

Pembrolizumab

Age Groups: adult

No variant requirements are available.